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Goundappa K Balasubramani, Deborah Hirtz, for the Paediatric Traumatic Brain Injury Consortium
Summary
Background On the basis of mixed results from previous trials, we assessed whether therapeutic hypothermia for 
48–72 h with slow rewarming improved mortality in children after brain injury.
Methods In this phase 3, multicenter, multinational, randomised controlled trial, we included patients with severe 
traumatic brain injury who were younger than 18 years and could be enrolled within 6 h of injury. We used a computer-
generated randomisation sequence to randomly allocate patients (1:1; stratiﬁ ed by site and age [<6 years, 6–15 years, 
16–17 years]) to either hypothermia (rapidly cooled to 32–33°C for 48–72 h, then rewarmed by 0·5–1·0°C every 
12–24 h) or normothermia (maintained at 36·5–37·5°C). The primary outcome was mortality at 3 months, assessed 
by intention-to-treat analysis; secondary outcomes were global function at 3 months after injury using the Glasgow 
outcome scale (GOS) and the GOS-extended pediatrics, and the occurrence of serious adverse events. Investigators 
assessing outcomes were masked to treatment. This trial is registered with ClinicalTrials.gov, number NCT00222742. 
Findings The study was terminated early for futility after an interim data analysis on data for 77 patients (enrolled 
between Nov 1, 2007, and Feb 28, 2011): 39 in the hypothermia group and 38 in the normothermia group. We detected 
no between-group diﬀ erence in mortality 3 months after injury (6 [15%] of 39 patients in the hypothermia group vs 
two [5%] of 38 patients in the normothermia group; p=0·15). Poor outcomes did not diﬀ er between groups (in the 
hypothermia group, 16 [42%] patients had a poor outcome by GOS and 18 [47%] had a poor outcome by GOS-extended 
paediatrics; in the normothermia group, 16 [42%] patients had a poor outcome by GOS and 19 [51%] of 37 patients 
had a poor outcome by GOS-extended paediatrics). We recorded no between-group diﬀ erences in the occurrence of 
adverse events or serious adverse events.
Interpretation Hypothermia for 48 h with slow rewarming does not reduce mortality of improve global functional 
outcome after paediatric severe traumatic brain injury. 
Funding National Institute of Neurological Disorders and Stroke and National Institutes of Health.
Introduction
Despite preventive measures, severe traumatic brain 
injury remains a leading cause of paediatric deaths and 
permanent disability around the world.1–3 Therapeutic 
regimens for paediatric traumatic brain injury, which are 
often derived from adult studies, have not been shown to 
be successful in improving outcome in children.
Therapeutic hypothermia has been shown to prevent 
or reduce secondary injury in animal experiments 
through several mechanisms including decreased 
cerebral metabolic demands, inﬂ ammation, lipid 
peroxidation, excitotoxicity, and cell death, with 
improved outcomes after experimental traumatic brain 
injury in mature and immature animals.4–8 Therapeutic 
hypothermia for 24–48 h was also successful in phase 2 
and 3 clinical studies9 of adults after traumatic 
brain injury and in several clinical trials in newborn 
babies after hypoxic-ischaemic encephalopathy,10 with 
improved outcomes,11 particularly mortality. Thus, the 
paediatric guidelines12,13 concluded that further study 
was needed to establish the eﬀ ect of temperature 
regulation and hypothermia in children after severe 
traumatic brain injury. 
Although a multicentre, phase 3, randomised controlled 
trial of moderate hypothermia in adults was stopped early 
owing to futility,14 post-hoc analysis drew attention to the 
potential for eﬀ ectiveness in younger patients (aged 
<18 years). A phase 3, multicentre, international (Canada 
and Europe) randomised controlled trial of hypothermia 
(at 32·0–33·0°C) for 24 h initiated within 8 h of severe 
traumatic brain injury in children and adolescents 
reported that hypothermia worsened outcomes at 
6 months post-injury and possibly increased mortality 
(21% vs 14%; p=0·06).15 However, issues related to study 
design raised concerns about the study ﬁ ndings.4 
Questions remained as to whether altering diﬀ erent 
parameters—ie, early or extended cooling period—would 
improve outcome.15,16
In view of the results of our phase 2 trial showing 
reduced mortality using hypothermia in children after 
severe traumatic brain injury,16 we aimed to assess 
whether hypothermia improved outcome—particularly 
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mortality—after injury. Also, on the basis of ﬁ ndings 
from our preliminary work16 and issues from the previous 
randomised controlled trial,5 our study was designed to 
ensure early randomisation and initiation of cooling, 
longer cooling periods, slower rewarming, and strict 
protocols for management of patients compared with 
previous paediatric severe traumatic brain injury 
hypothermia trials.
Methods
Study sites and participants
The Paediatric Traumatic Brain Injury Consortium: 
Hypothermia (the Cool Kids Trial) was a multinational, 
multicentre, phase 3 randomised controlled trial 
assessing the eﬀ ect on mortality of moderate hypothermia 
with slow rewarming after paediatric severe traumatic 
brain injury. Hypothermia was maintained for 48–72 h in 
conjunction with standardised head injury management 
and compared with normothermia. Patients were 
enrolled in the emergency department or intensive care 
unit at study hospitals within 6 h of injury from 15 sites 
in the USA, New Zealand, and Australia. Parents or 
guardians of all participants provided written informed 
consent before enrolment. In some hospitals, children 
were enrolled via an emergency waiver of consent. 
Patients were eligible for inclusion if they were aged 
0–17 years; had non-penetrating brain injury, a Glasgow 
coma scale score of 3–8, and a motor score on the Glasgow 
coma scale of less than 6 after resuscitation; and were 
available for randomisation within 6 h of injury (which 
required known injury time, to exclude children with non-
accidental trauma). Patients were excluded if they had a 
normal CT, a Glasgow coma scale score of 3, unreactive 
pupils, hypotension (deﬁ ned as systolic blood pressure 
<5th percentile for age) for more than 10 min, uncorrectable 
coagulopathy (prothrombin time/partial thromboplastin 
time >16/40 s, international normalised ratio >1·7), 
hypoxia (deﬁ ned as oxygen saturation <90% for >30 min 
after resuscitation), abbreviated injury severity score of 4 or 
greater for organs other than the brain, suspected 
pregnancy, or unavailable parent or guardian to consent (at 
some study sites—those without emergency waiver of 
consent). The trial protocol was approved by the 
Institutional Review and Ethics Boards at each participating 
centre and allowed emergency waiver of consent (at ﬁ ve of 
the 15 study sites) if a family member was unavailable.
Randomisation and masking
Patients were randomly assigned in a one-to-one ratio, 
stratiﬁ ed by site and age (<6 years, 6–15 years, 16–17 years), 
to hypothermia or normothermia using a web-based 
random assignment algorithm. Ran domisation was done 
by the site study coordinator after screening for eligibility. 
Investigators who assessed outcome were masked to 
treatment allocation. Emergency service personnel, study 
nurses involved in randomisation, and personnel who 
managed the patients were unmasked to treatment 
2140 children screened
561 screened 
172 eligible for enrolment
77 enrolled
39 randomised to 
hypothermia
38 randomised to 
normothermia
13 included in 
run-in phase
59 no consent obtained
23 refused enrolment
15 did not want to 
be in research
1 did not want to 
be randomised
7 other
389 excluded
60 arrived >6 h from 
injury
160 had a post-injury 
GCS of 3
38 had normal CT
33 had penetrating TBI
50 brain dead
53 no known mechanism
16 no known time 
of injury
92 abuse
114 unable to randomise 
within 6 h
40 coagulopathy
70 hypotensive
44 hypoxia
1 pregnancy
1579 excluded
1541 GCS >8
1306 GMS >6
44 were ≥16 years* 
Figure 1: Trial proﬁ le
Patients could have been excluded for more than one of the listed reasons. GCS=Glasgow coma scale. 
GMS= Glasgow motor score. TBI=traumatic brain injury. *Before expansion of inclusion criteria to patients older 
than 16 years but younger than 18 years on Feb 1, 2010.  
Panel 1: Tiered protocol for the management of patients (both hypothermic and 
normothermic)
 Patients were started on tier-one treatment. If treatment failed, the patient was started 
on tier-two treatment.
Tier one
• Head in a neutral position at 0–30° elevation.
• Intermittent or continuous ventricular drainage of CSF.
• Systemic neuromuscular paralysis (pancuronium or vecuronium) with sedation 
(conﬁ rmed by non-movement on a twitch monitor) or sedation alone with a 
continuous infusion of narcotic (fentanyl or morphine).
• Sedation followed by hyperosmolar therapy with either mannitol (initially at 
0·25 g/kg every 4–6 h, with escalation to 0·5–1 g/kg until serum osmolality was 
greater than 320 mOsm per kg) or hypertonic saline (3%) continuous drip (started at 
0·1–0·5 mL/kg, up to 1·0 mL/kg, titrated to eﬀ ect to maintain serum osmolality less 
than 360 mOsm per kg) as needed for intracranial pressure increases. 
Tier two
• Treating clinician’s choice of the following: 
• Option one: barbiturates, initially 5 mg/kg every 4–6 h, with escalation to coma 
with 80–90% burst suppression by continuous electroencephalogram monitoring 
10 s epochs (pressors and further volume expansion were used to maintain 
central venous pressure, cerebral perfusion pressure, and mean arterial pressure, 
and to avoid hypotension with higher doses of barbiturates or narcotics). 
• Option two: decompressive craniectomy, contusion excision, or both, or temporal 
lobectomy for failure of medical management.
• Phenytoin was given to all patients at 20 mg/kg followed by maintenance doses 
(of 5 mg per kg per day in three divided doses) for 7 days.
• Blood gases were not corrected for body temperature. 
• Central venous pressures and volume and serum potassium concentrations were 
monitored and treated with intravenous replacement, except for before and during 
rewarming. PaCO2 less than 30 mm Hg was avoided through controlled ventilation 
when possible.
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allocation. Anyone involved in obtaining outcomes and 
outcome data including, psychologists, neuro-
psychologists, and or neuropsychology technicians, were 
masked to treatment. A run-in period was used to ensure 
patient safety and data quality. Requirements for the 
study to pass beyond the run-in period included entry of 
one patient assigned to hypothermia and managed 
according to protocol, and transfer of all necessary data to 
the data centre. Data from patients in the run-in phase 
were not included in the analysis.
Procedures
All emergency treatment procedures and speciﬁ c 
guidelines for head injury management were based on 
paediatric guidelines12 and other standardised operating 
protocols agreed to by consensus of all the site 
investigators. We used a standard servo-controlled cooling 
and heating blanket unit placed underneath the patient 
for temperature regulation and to cool or rewarm patients 
to the target temperature. Children’s temperatures were 
taken with rectal or brain temperature probes.
Patients in the hypothermia group were rapidly cooled 
initially using iced saline (4°C) to 34–35°C and then 
surface cooled to 32–33°C and maintained for the requisite 
48 h period. The patient was then rewarmed by 0·5–1·0°C 
every 12–24 h as part of a slow rewarming protocol. If at 
48 h their intracranial pressure (ICP) was high 
(>20 mm Hg) a further 24 h of cooling at target (32–33°C) 
was maintained. At this point, rewarming occurred, 
irrespective of ICP levels, albeit slowly (<1·0°C every 24 h) 
to prevent rebound intracranial hypertension. Patients in 
the normothermia group were maintained at 36·5–37·5°C. 
Patients with temperatures greater than 38°C were treated 
with rectal acetaminophen and cooling blankets.
The main goals of therapy in intensive care units and 
operating rooms were to avoid hypotension, hypoxia, and 
intracranial hypertension by: maintaining mean arterial 
pressure (MAP) at within two SD of the mean for their 
age,12,13 peripheral oxygen saturation greater than 90%, and 
ICP less than 18 mm Hg (for children aged <6 years), ICP 
of 20 mm Hg or lower (≥6 years), and or cerebral perfusion 
pressure greater than MAP (for their age) plus 20 mm Hg. 
A two-tiered protocol was followed in a stepwise linear 
manner with failure of the ﬁ rst-tier treatment dictating 
escalation to second tier treatments (panel 1). All 
physiological data, daily ﬂ uid volumes, drugs and dosages, 
neurological and Glasgow coma score, and daily paediatric 
intensity level of therapy scores were recorded over the 
ﬁ rst 7 days of admission to hospital.167
Our primary outcome, assessed by intention-to-treat 
analysis, was mortality at 3 months after injury.
We hypothesised that induced early cooling (<6 h) with 
hypothermia (32–33°C) after paediatric severe traumatic 
brain injury maintained for 48 h would reduce all-cause 
mortality at 3 months after injury compared with 
normothermia (36·5–37·5°C). The secondary outcome 
measures were global function at 3 months after injury 
using the Glasgow outcome scale (GOS) and Glasgow 
outcome scale-extended pediatrics (GOS-E Peds) as well 
as the occurrence of serious adverse events and adverse 
events. GOS scores were dichotomised into good 
outcomes for good or moderate functional disability 
(GOS 1 and 2, respectively) or poor outcomes for those 
who were severely disabled, were vegetative, or died 
(GOS 3, 4, or 5, respectively). GOS-E Peds scores were 
also dichotomised into good outcomes (GOS-E Peds 1–3) 
and poor outcomes (GOS-E Peds 4–8). 
Statistical analysis
On the basis of ﬁ ndings from our previous trial,16 the 
planned sample size was 340 patients, which would allow 
detection of a 10% diﬀ erence in the percentage of patients 
who died with 80% power. An interim analysis of 
outcome and complications was planned at the midpoint 
of the trial (when 170 people had been enrolled). Interim 
Total 
(N=77)
Therapeutic 
hypothermia 
(N=39)
Normothermia 
(N=38)
Boys 48 (62%) 21 (54%) 27 (71%)
Ethnic origin
White 58 (75%) 26 (67%) 32 (84%)
Black 12 (16%) 9 (23%) 3 (8%)
Other 7 (9%) 4 (10%) 3 (8%)
Hispanic 16 (21%) 6 (15%) 10 (26%)
Cause
Fall 13 (17%) 9 (23%) 4 (11%)
Motor vehicle collision 51 (66%) 25 (64%) 26 (68%)
Assault 1 (1%) 0 1 (3%)
Other 12 (16%) 5 (13%) 7 (18%)
Right pupil reaction
Data not available 1 (1%) 0 1 (3%)
Normal 34 (46%) 16 (44%) 18 (47%)
Sluggish 23 (31%) 12 (33%) 11 (29%)
Fixed 16 (22%) 8 (22%) 8 (21%)
Left pupil reaction
NA 1 (1%) 0 1 (3%)
Normal 36 (49%) 15 (42%) 21 (55%)
Sluggish 24 (32%) 16 (44%) 8 (21%)
Fixed 13 (18%) 5 (14%) 8 (21%)
Number of ﬁ xed pupils
None 53 (73%) 26 (72%) 27 (73%)
One 11 (15%) 7 (19%) 4 (11%)
Two 9 (12%) 3 (8%) 6 (16%)
Apnoea 6 (9%) 2 (5%) 4 (11%)
Aspiration 12 (17%) 7 (19%) 5 (14%)
Cardiac arrest 2 (3%) 1 (3%) 1 (3%)
Hypotension 6 (8%) 4 (11%) 2 (6%)
Hypoxia 10 (13%) 7 (18%) 3 (8%)
Seizure 12 (16%) 4 (10%) 8 (21%)
Data are number of patients (%). NA=data not available.
Table 1: Baseline characteristics
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analyses were done every 6 months in conjunction with 
the data safety and monitoring board meeting. A group 
sequential analytic approach was used to adjust the 
overall type-1 error for multiple comparisons. Stopping 
rules stated that the trial should be terminated at the 
futility or interim analysis if there was less than a 20% 
chance of conﬁ rming the primary hypothesis. 
Baseline characteristics by treatment group are reported 
as means and SDs for continuous variables and 
percentages for discrete variables. We compared functional 
outcomes and the occurrence of serious adverse events 
using a Pearson χ² test or a Fisher’s exact test. We used a 
logistic regression model to assess the probability of 
mortality up to 3 months after injury; we selected this 
model because we wanted to assess the association of 
treatment with mortality by a speciﬁ c timepoint, not to 
estimate the risk of mortality at any given time. We used 
SAS (version 9.2) for statistical analyses, which included 
only patients randomly allocated to the one of the two 
treatment groups only (ie, no run-in patients). 
This trial is registered with ClinicalTrials.gov, number 
NCT00222742.
All (N=77) Hypothermia (N=39) Normothermia (N=38)
n Median (IQR) n Median (IQR) n Median (IQR)
Age (years) 77 10·9 (3·4–14·6) 39 9·7 (4·2–14·5) 38 12·5 (3·3–14·8)
Height (cm) 72 136·5 (100·5–165) 37 137 (110–167) 35 135 (94–161)
Weight (Kg) 77 32 (16–60) 39 30 (15·4–62) 38 38 (16–60)
Glasgow coma scale score 77 6 (5–7) 39 6 (5–7) 38 6 (5–7)
Body mass index 72 18·5 (16–21·4) 37 18·8 (16–22) 35 18 (16–21)
Right pupil size (mm) 73 3 (2–4) 35 4 (3–4) 38 3 (2–3)
Left pupil size (mm) 73 3 (2–4) 35 3 (3–4) 38 3 (2–3)
AIS-head 77 4 (4–5) 39 4 (3–5) 38 4 (4–5)
AIS-face 77 1 (0–2) 39 1 (0–2) 38 1 (0–2)
AIS-neck 77 0 (0–0) 39 0 (0–0) 38 0 (0–0)
AIS-thorax 77 0 (0–2) 39 0 (0–2) 38 0 (0–0)
AIS-abdomen 77 0 (0–0) 39 0 (0–0) 38 0 (0–1)
AIS-spine 77 0 (0–0) 39 0 (0–0) 38 0 (0–0)
AIS-upper extremities 77 0 (0–1) 39 0 (0–1) 38 0 (0–0)
AIS-lower extremities 77 0 (0–1) 39 0 (0–1) 38 0 (0–1)
AIS-external 77 0 (0–0) 39 0 (0–1) 38 0 (0–0)
AIS=Abbreviated injury severity.
Table 2: Clinical characteristics by treatment group
Figure 2: Outcomes at 3 months after injury
Outcomes in terms of Glasgow outcome scale (GOS; A) and GOS-extended paediatrics (GOS-E Peds; B). A GOS of 5 and a GOS-E Peds of 8 corresponds to mortality; a 
score of 1 corresponds to normal functioning for both measures. p values are for comparison between therapeutic hypothermia and normothermia.
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Role of the funding source
The sponsor had no role in data collection, analysis, or 
interpretation, or in writing the report, but was involved 
in study design and chose the timing of the futility 
analysis. The corresponding author had full access to all 
the data at the completion of the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Because of slow accrual and concerns from the data 
safety and monitoring board about safety data from 
another randomised controlled trial15 in children with 
severe traumatic brain injury treated with hypothermia 
for 24 h (p=0·14), a futility analysis was done and the trial 
was stopped in Feb 28, 2011. 
We had randomly allocated 77 patients to treatment: 
39 to hypothermia and 38 to normothermia (written 
consent was given for 74 patients, the other three had an 
emergency waiver of consent; ﬁ gure 1). 
Three hypothermia-treated patients were later found to 
meet exclusion criteria: one child had an unknown time of 
injury related to assault, one child had a complete spinal 
cord injury and physiological decapitation (both children 
later died), and one child improved after resuscitation to a 
Glasgow coma scale score greater than 8. No patients in 
the normothermia group later met exclusion criteria. 
Three sites enrolled 75% of the randomised patients: 
Children’s Hospital of Pittsburgh, PA, USA (23 patients), 
University of California, Davis, CA, USA (12 patients), and 
University of Texas, Southwestern, TX, USA (ten patients). 
Follow-up for primary and secondary outcome measures 
continued until May 28, 2011.
Baseline characteristics were much the same between 
the two groups apart from the median size of the right 
pupil, which was larger in the hypothermia group than it 
was in the normothermia group (tables 1 and 2).
The primary outcome of mortality within 3 months of 
injury, available for all 77 patients, did not diﬀ er between 
hypothermia-treated patients (6 [15%] of 39 patients) and 
normothermia-treated patients (2 [5%] of 38 patients; 
p=0·15) when the trial was stopped. Secondary outcome 
data were missing for two patients: one (in the 
hypothermia group) was lost to follow-up at 3 months for 
global function, and one (in the normothermia group) 
had missing data for GOS-E Peds. We detected no 
signiﬁ cant diﬀ erence between the interventions in 
categorical GOS and GOS-E Peds scores (ﬁ gure 2) or in 
the dichotomised (good or poor) GOS and GOS-E Peds 
scores at 3 months (table 3). 
37 (95%) of 39 patients assigned to hypothermia were 
cooled for at least 48 h before rewarming; one progressed 
rapidly to brain death before cooling and the other 
improved substantially and was rewarmed before 
completing 48 h of cooling. Of the remaining 37 cooled 
patients, mean time to randomisation and initiation of 
cooling was 5 h 8 min (SD 55 min) after injury, although 
three patients who were allocated to the hypothermia 
group before 6 h after injury began cooling at more than 
6 h after injury. All patients in the hypothermia group 
reached target temperature (32–33°C) with mean time to 
target from injury of 9 h 0 min (3 h 10 min; range 
4 h 31 min to 22 h 18 min). Seven (18%) of 38 patients 
reached target within 2 h of initiation of cooling (range 
0 h 0 min to 1 h 58 min).
Mean temperature for the 48 h period of hypothermia 
was 32·9°C (SD 0·8) and for the concurrent 48 h period 
in the normothermia group was 36·9°C (SD 0·7; 
p<0·0001 for between-group diﬀ erence). No patient 
assigned to normothermia was cooled lower than 36·5°C. 
Normothermic temperature (36·5–37·5°C) was main-
tained for 48 h in 12 (32%) of 38 patients in the 
normothermia group. Rewarming for hypothermia 
patients occurred with a mean temperature of 32·8°C 
(SD 0·5) with mean time of rewarming to 
36°C of 60 h 5 min (SD 26 h 26 min; ﬁ gure 3). 
We recorded no diﬀ erences in medical management, 
mean arterial pressure, or cumulative ﬂ uid balances 
between the treatment groups, but a higher proportion of 
Total Hypothermia Normothermia
Glasgow outcome scale*
Good outcome (scores 1–2) 44/76 (59%) 22/38 (58%) 22/38 (58%)
Poor outcome (scores 3–5) 32/76 (41%) 16/38 (42%) 16/38 (42%)
Glasgow outcome scale-extended pediatrics†
Good outcome (scores 1–4) 38/75 (51%) 20/38 (53%) 18/37 (49%)
Poor outcome (scores 5–8) 37/75 (49%) 18/38 (47%) 19/37 (51%)
Data are number of patients (%). *Between-group diﬀ erence (p value=0·90). †Between-group diﬀ erence (p value=0·73). 
Despite random assignment, there were missing data for two patients: one patient was lost to follow-up at 3 months, 
and Glasgow outcome scale-extended pediatrics  data were missing for one patient in the normothermia group.
Table 3: Secondary outcomes at 3 months after injury
Figure 3: Temperatures of patients during the ﬁ rst 5 days after randomisation
Error bars are SDs.
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patients in the normothermia group underwent 
decompressive craniectomy treatment than in the 
hypothermia group (17 [45%] of 38 patients vs 7 [18%] 
39 patients; p=0·0220). During the ﬁ rst 120 h, the 
number of interventions for intracranial hypertension, as 
indicated by mean paediatric intensity level of therapy 
scores (modiﬁ ed by excluding the score for induced 
hypothermia) were 5·6 (SD 2·4) with hypothermia and 
6·4 [2·7] with normothermia (p=0·079). We recorded no 
diﬀ erences in the laboratory data between treatment 
groups for blood chemistries, coagulation parameters, or 
arterial blood gas values for partial pressure of arterial 
oxygen concentrations lower than 100 mm Hg or carbon 
dioxide concentrations lower than 30 mm Hg. 
We recorded no diﬀ erences between treatment groups 
in the percentage of any individual complication or group 
of complications, whether critical or non-critical (table 4). 
We recorded no diﬀ erence in the number of serious 
adverse events per person, the number of adverse events 
per person, the percentage of patients with any serious 
adverse event, or the percentage of patients with any 
adverse events (table 4). 
Discussion
This trial was stopped due to futility because hypothermia, 
initiated early, used globally for 48–72 h, and with a slow 
rewarming period, did not improve mortality or global 
function 3 months after injury compared with 
normothermia. Although many therapeutic interventions 
for severe traumatic brain injury have been used and 
tested in clinical trials, no new treatment regimens—for 
adults or children—have been shown to be eﬀ ective.5,18,19 
Hypothermia has alleviated secondary brain injury after 
acute brain injury in both adult and immature animal 
models of injury, including traumatic brain injury.7,8,20–24 
This trial expanded on the few previous, limited, and 
small-scale, hypothermia clinical studies in paediatric 
severe traumatic brain injury and on the only three 
randomised controlled trials (panel 2). Findings from an 
international phase 3 multicentre randomised controlled 
trial of hypothermia15 in 225 children with severe 
traumatic brain injury indicated that delayed initiation of 
cooling, cooling for up to 24 h, rapid rewarming, and 
hypotension in the acute period after injury should be 
avoided. Thus, in the present study, we attempted to build 
on the available evidence by starting cooling earlier, for a 
longer duration (48 h), and with slow rewarming while 
maintaining perfusion by avoiding hypotension with 
ﬂ uids and pressors. We saw no diﬀ erence in mortality or 
3 month global function, as was the case in the other 
randomised controlled trials of hypothermia in adults9,14 
and in children,15 but by contrast with our previous 
phase 2 trial in which hypothermia improved mortality.16 
There are several limitations and potentially confounding 
variables (ie, age-related changes in brain development, 
similar aged children at diﬀ erent levels of maturity) in 
clinical trials for traumatic brain injury, especially in trials 
done with children. Other design approaches can be 
considered that would increase the necessary sample size. 
Although the Glasgow coma score has been the mainstay 
for initial assessment of severity of brain injury and then 
inclusion in clinical trials, the types and variability of 
pathology seen on imaging despite similar Glasgow coma 
score emphasise the need for improved initial assessment 
for stratiﬁ cation into clinical studies. For example, 
hypothermia might have selective eﬃ  cacy in particular 
types of pathology—eg, surgically evacuated haematomas 
versus diﬀ use injury—which could be used as the selection 
criteria rather than Glasgow coma score.29 
Despite consensus of site investigators to a step-wise 
clinical pathway for management of intracranial 
pressure, application of that algorithm varied both within 
and between sites, with variations in treatment potentially 
confounding results and contributing to futility. In 
Total 
(N=77)
Therapeutic 
hypothermia 
(N=39)
Normothermia 
(N=38)
p value
Serious adverse events
Total 78 34 44 ··
Death 8 (10%) 6 (18%) 2 (5%) ··
Uncontrollable intracranial      
hypertension
7 5 2 ··
Occipital-atlantial dislocation 1 1 0 ··
Infection 7 (9%) 2 (6%) 5 (12%) ··
Hypotension 4 (5%) 3 (9%) 1 (2%) ··
Haemorrhage 5 (6%) 3 (9%) 2 (5%) ··
Pulmonary 7 (9%) 5 (15%) 2 (5%) ··
Arrhythmias 1 (1%) 1 (3%) 0 ··
Other 46 (59%) 14 (41%) 32 (73%) ··
Adverse events
Total 216 123 93 ··
Acute (<120 h after injury) 
non-serious infection
128 79 49 ··
Pneumonia 16 (13%) 7 (9%) 9 (19%) ··
Other infections 58 (45%) 43 (54%) 15 (30%) ··
Coagulopathy 53 (41%) 29 (37%) 24 (49%) ··
Post-traumatic seizures 1 (1%) 0 1 (2%) ··
Late (>120 h after injury) 
non-serious infection
88 44 44 ··
Ventriculitis 1 (1%) 0 1 (2%) ··
Pneumonia 11 (13%) 6 (14%) 5 (11%) ··
Other infections 49 (56%) 23 (52%) 26 (59%) ··
Deep vein thrombosis requiring 
treatment
5 (6%) 3 (7%) 2 (5%) ··
Coagulopathy 18 (20%) 9 (20%) 9 (20%) ··
Post-traumatic seizures 4 (5%) 3 (7%) 1 (2%) ··
Serious adverse events per person 2·0 (1·2) 1·6 (0·9) 2·3 (1·3) 0·0622
Any serious adverse events 40/77 (52%) 21/39 (54%) 19/38 (50%) 0·7356
Adverse event per person 7·3 (6·4) 8·2 (6·5) 6·3 (6·2) 0·2362
Any adverse event 69/77 (90%) 36/39 (92%) 33/38 (87%) 0·4320
Data are n (%), mean (SD), or n/N (%).  
Table 4: Adverse events
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particular, decompressive craniectomy was used for 
intracranial pressure control in more patients in the 
normothermia group than in the hypothermia group. 
Further prospective studies of a large number of patients, 
across multiple centres, are needed to assess the 
comparative eﬀ ectiveness of this variability in the 
management of these children and their intracranial 
hypertension. 
Similarly, outcome assessment after injury is not easily 
deﬁ ned. On the basis of our previous ﬁ ndings,16 we used 
mortality as our primary outcome measure for the present 
study because its measurement gave the largest diﬀ erence 
in our paediatric patients, and we used it to calculate the 
sample size. During the accrual period for this study, 
mortality of children after brain injury in the USA 
decreased overall, lessening the power of the study. 
Furthermore, during the accrual period, the incidence of 
non-accidental trauma as the mechanism of injury 
seemed to increase. Because this type of injury was an 
exclusion criteria (because of diﬃ  culty in determining the 
exact time of injury), many children with severe non-
accidental injuries were excluded, further reducing power. 
In children, traumatic brain injury aﬀ ects not only a 
wide range of functional abilities, but also normal 
development,30 and global outcome measures (GOS and 
GOS-E Peds) that depend heavily on parent or caregiver 
report of signs and symptoms might have little usefulness 
in the assessment of functional outcome after paediatric 
brain injury.
Finally, consent could not be obtained for many 
potentially eligible patients for the following reasons: 
distance to paediatric study centres (parents or guardians 
were often not available for consent within the requisite 
time for randomisation and initiation of cooling); inability 
to obtain emergency waiver of consent at most of the sites 
(present day regulations and compliance for emergency 
waiver requirements—eg, community education—cannot 
be budgeted into the cost of the study and are often 
prohibitively expensive in large studies); and a higher rate 
of refusal of consent from parents and guardians than in 
the previous study. The reasons for the higher rate of 
refusals are unclear, but this ﬁ nding does cause concern 
for future studies of acute therapeutic intervention if 
accessibility to paediatric patients becomes diﬃ  cult. 
Further clinical trials will need improved stratiﬁ cation 
by injury and alternative outcome measures if they are to 
be able to establish the potential of hypothermia to treat 
children with severe traumatic brain injury.
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Panel 2: Research in context
Systematic review
We searched Medline (from Jan 1, 1950, to Feb 1, 2013) and 
the Cochrane Central Register of Controlled Trials (The 
Cochrane Library issue 1, 2013) for human studies with the 
following MeSH search terms: “brain injuries”[MeSH terms] 
OR (“brain”[all ﬁ elds] AND “injuries”[all ﬁ elds]) OR “brain 
injuries”[all ﬁ elds] OR (“traumatic”[all ﬁ elds] AND “brain” 
[all ﬁ elds] AND “injury”[all ﬁ elds]) OR “traumatic brain 
injury”[all ﬁ elds] (TBI) AND outcome [all ﬁ elds]; AND (Clinical 
Trial[ptyp]). We repeated the search adding the terms, 
“children” and “paediatric”. All types of trial design with at 
least three patients were reviewed and considered. All 
included clinical trials were assessed for methodological 
quality—in terms of the randomisation generation, double 
blinding, and proportion of patients lost to follow-up.
Interpretation
We identiﬁ ed only three randomised controlled clinical 
trials15,16,25 that tested therapeutic hypothermia after severe 
traumatic brain injury in children. Biswas and colleagues’ trial25 
was a small study underpowered for outcome and its ﬁ ndings 
were inconclusive with respect to mortality, although it did 
show that hypothermia lowered intracranial pressure. We 
previously reported a phase 2 randomised controlled trial in 
which moderate hypothermia (32–33°C) for 48 h did improve 
outcome (Glasgow outcome scale) with decreased mortality.17 
Since our previous study, phase 3 randomised trials were done 
by Clifton and colleagues9,14 in adults (moderate hypothermia, 
early cooling, for 48 h, and then slow rewarming) and 
Hutchison and colleagues15 in children (moderate hypothermia 
for 24 h, then rapid rewarming), all reporting no improvement 
in mortality or global functional outcome after severe 
traumatic brain injury. The present study was stopped early 
owing to futility, showing that moderate hypothermia 
(32–33°C) for 48–72 h with slow rewarming after severe 
paediatric traumatic brain injury did not improve outcome 
with regard to mortality or global function at 3 months after 
injury. These few studies have not shown beneﬁ cial eﬀ ects of 
therapeutic hypothermia in the clinical setting after paediatric 
brain injury. Further research might be beneﬁ cial to assess 
whether there is the potential eﬃ  cacy of therapeutic 
hypothermia in severe traumatic brain injury in children under 
other circumstances. Such studies could include investigation 
of cooling temperature, timing, and injury type, as well as long 
term follow-up with alternative measures.
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